CAMBRIDGE, Mass., January 31, 2023 – Casma Therapeutics, a biotechnology company engaging the autophagy system to provide innovative new medicines, today announced that Keith Dionne, Ph.D., has stepped down as Chief Executive Officer, effective January 13, 2023. Dr. Dionne will continue to serve on the Board of Directors. Frank Gentile, Ph.D., formerly Chief Operating Officer […]
CAMBRIDGE, Mass., November 10, 2021 – Casma Therapeutics, Inc., a biotechnology company harnessing the power of autophagy to design innovative new medicines, today announced that Chief Executive Officer, Keith Dionne, Ph.D., will present at the upcoming Stifel Virtual Healthcare Conference on Wednesday, November 17, 2021 at 10 a.m. ET.
About Casma Therapeutics
Casma Therapeutics is harnessing autophagy by developing novel degradation approaches to open new target areas for drug discovery and development that will profoundly impact the lives of patients. Autophagy is a conserved cellular process that contributes to overall cellular homeostasis, but when autophagy is perturbed, inefficient autophagic flux contributes to numerous diseases. By selectively boosting autophagy and degradation of disease targets in the lysosome, Casma expects to be able to arrest or reverse the progression of disease processes such as neurodegeneration, metabolic disorders, inflammation, muscle degeneration and oncology. For more information, please visit www.casmatx.com.
Stern Investor Relations, Inc.
January 31, 2023Casma Therapeutics Announces CEO Transition
January 30, 2023Casma Therapeutics Announces new Nature Publication – “Structure of the lysosomal mTORC1–TFEB–Rag–Ragulator megacomplex”
In their recent Nature paper, Casma Founders Jim Hurley and Andrea Ballabio describe the cryogenic-EM structure of an MTORC1 megacomplex. A molecular description of this massive complex is helping us understand the regulation of the TFEB transcription factor and dependence of TFEB phosphorylation on FLCN and the RagC GDP state. Read full publication here